Literature DB >> 27906194

A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants.

A Cuna1,2,3, S Govindarajan1, A Oschman2, H Dai2, K Brophy4, M Norberg2,3, W Truog1,2,3.   

Abstract

OBJECTIVE: The objective of the study was to compare the effect of two different dexamethasone regimens on respiratory outcomes of ventilator-dependent preterm infants. STUDY
DESIGN: Retrospective study of ventilated preterm infants <29 weeks gestational age treated with either 7-day or 10-day dexamethasone course. Primary outcome was days to successful extubation. Other outcomes included rate of successful extubation and need for repeat steroid therapy.
RESULTS: Fifty-nine infants were identified; 32 (54%) received 7 days of dexamethasone and 27 (46%) received 10 days of dexamethasone. Both groups had comparable baseline demographics and clinical characteristics. Mean time to successful extubation was similar between the two groups (5.1±2.7 days in 7-day group and 6.0±3.7 days in 10-day group, P=0.42). Successful extubation by end of treatment (56% versus 67%, P=0.44) and need for repeat steroid therapy (47% versus 33%, P=0.43) were also similar.
CONCLUSION: 7-day and 10-day course of dexamethasone have comparable efficacy in facilitating extubation of ventilator-dependent preterm infants.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27906194     DOI: 10.1038/jp.2016.215

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  2 in total

1.  Let's Talk about Dex: When do the Benefits of Dexamethasone for Prevention of Bronchopulmonary Dysplasia Outweigh the Risks?

Authors:  Thuy Nguyen; Brian K Jordan
Journal:  Newborn (Clarksville)       Date:  2022-03-31

2.  Efficacy of late postnatal dexamethasone on weaning from invasive mechanical ventilation in extreme premature infants.

Authors:  Waleed Kurtom; Augusto Schmidt; Deepak Jain; Silvia Vanbuskirk; Alini Schott; Eduardo Bancalari; Nelson Claure
Journal:  J Perinatol       Date:  2021-05-28       Impact factor: 2.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.